← Back to Search

Further Enhancing Non-pharmacologic Therapy for Incontinence

N/A
Waitlist Available
Led By Neil M Resnick, MD
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

To determine the mechanisms mediating the therapeutic efficacy of pelvic floor muscle exercises and biofeedback for urge urinary incontinence, as well as the characteristics of patients most likely to respond. By identifying the key components of this treatment, we hope to simplify it and make it more easily applicable, more effective, less expensive, and thus more useful for people with urge incontinence in the future.

Eligible Conditions
  • Urge Incontinence

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: BiofeedbackExperimental Treatment1 Intervention
Biofeedback assisted pelvic floor muscle therapy (3 visits)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biofeedback, pelvic floor muscle training, fMRI
2004
N/A
~130

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH
1,805 Previous Clinical Trials
28,194,734 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,843 Previous Clinical Trials
8,173,110 Total Patients Enrolled
University of PittsburghLead Sponsor
1,792 Previous Clinical Trials
16,359,863 Total Patients Enrolled
Becky Clarkson, PhDStudy DirectorUniversity of Pittsburgh
3 Previous Clinical Trials
471 Total Patients Enrolled
Neil M Resnick, MDPrincipal InvestigatorUniversity of Pittsburgh
1 Previous Clinical Trials
190 Total Patients Enrolled
~6 spots leftby Jan 2026